Press Releases
Page 4 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
European Commission Approves POHERDY, First Pertuzumab Biosimilar in Europe by Henlius and Organon
EC grants marketing authorization for POHERDY (pertuzumab), the first approved biosimilar to PERJETA in Europe, developed by Henlius Biotech and Organon.
PureTech Reports Positive LYT-200 Clinical Results for Myeloid Malignancies in 2025 Annual Results
PureTech announces positive clinical results for LYT-200 in myeloid malignancies, alongside Phase 3-ready deupirfenidone and advancing neuropsychiatric pipeline.
EnteroBiotix Raises £19M to Launch Phase 2b Microbiome Trial for Irritable Bowel Syndrome Treatment
EnteroBiotix secures £19M funding to initiate the largest Phase 2b microbiome trial for IBS treatment, with patient dosing starting Q2 2026.
Ray Therapeutics RTx-015 Receives EMA PRIME Designation for Retinitis Pigmentosa Treatment
Ray Therapeutics' RTx-015 gene therapy receives EMA PRIME designation for retinitis pigmentosa, accelerating regulatory pathway for vision restoration treatment.
X4 Pharmaceuticals Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment in EU
X4 Pharmaceuticals announces European Commission approval for XOLREMDI (mavorixafor), the first authorized treatment for WHIM syndrome patients in the EU.
Norgine Receives European Approval for XOLREMDI (Mavorixafor), First WHIM Syndrome Treatment in EU
Norgine's XOLREMDI becomes the first authorized treatment for WHIM syndrome in Europe, marking a breakthrough for ultra-rare immunodeficiency patients.
Norgine Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment
Norgine's XOLREMDI becomes first authorized treatment for WHIM syndrome in Europe, marking breakthrough for ultra-rare immunodeficiency patients.
Henlius and Organon's POHERDY Becomes First Pertuzumab Biosimilar Approved in Europe
European Commission approves POHERDY as first pertuzumab biosimilar in Europe, offering cost-effective alternative to PERJETA for breast cancer treatment.
VivoSim Labs Launches AI Tool to Predict Drug-Induced Diarrhea Without Animal Testing
VivoSim Labs unveils AI prediction platform using human intestinal models to forecast gastrointestinal toxicity, eliminating need for animal testing.
Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 2 Obesity Trial, Outperforming Current Market Leaders
Survodutide delivered 39.2 lb average weight loss in 76-week trial, potentially superior to Wegovy and Zepbound in competitive obesity market.
Idorsia Reports 74% QUVIVIQ Sales Growth in Q1 2026, Expands European Market Reach
Idorsia's insomnia drug QUVIVIQ achieves 74% year-over-year sales growth in Q1 2026, with European expansion and pediatric data driving future growth.
Small Molecule API Market Projected to Reach $202.53 Billion by 2036 as Generic Drug Demand Surges
Small molecule API market set to hit $202.53 billion by 2036, driven by generic drug demand and oncology pipeline expansion across global markets.